868049-49-4

Basic information

• Product Name: 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one
• Synonyms: 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one;Olodaterol;Olodaterol ImpurityＡ;2H-1,4-Benzoxazin-3(4H)-one, 6-hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-;BI 1744(Olodaterol;Striverdi Respimat);BI-1744;Striverdi
• CAS NO: 868049-49-4
• Molecular Formula: C₂₁H₂₆N₂O₅
• Molecular Weight: 386.44
• EINECS: 1592732-453-0
• Mol File: 868049-49-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 649.05 °C at 760 mmHg
• Flash Point: 346.333 °C
• Appearance: /
• Density: 1.250
• PKA: 9.42±0.20(Predicted)
• CAS DataBase Reference: 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one(868049-49-4)
• EPA Substance Registry System: 6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one(868049-49-4)

Safety Data

• Hazardous Substances Data: 868049-49-4(Hazardous Substances Data)

Usage

Description

6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one, also known as olodaterol, is a member of the benzoxazine class of compounds. It is a potent and highly selective β2-adrenergic receptor agonist with a rapid onset of action and bronchoprotection over 24 hours. Olodaterol forms a highly stable complex with the β2-adrenergic receptor, with a dissociation half-life of 17.8 hours. It is used for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Uses

Used in Pharmaceutical Industry:
Olodaterol is used as a bronchodilator for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is delivered via the Respimat Soft Mist inhaler and has been approved for use in Russia, Canada, and the European Union.
Used in Drug Synthesis:
The synthesis of olodaterol proceeds through an (R)-styrene epoxide that is prepared via enantioselective reduction of an α-chloroketone intermediate. Ring opening of the epoxide with 1-(4-methoxyphenyl)-2-methylpropan-2-amine provides olodaterol. This synthesis process is used in the pharmaceutical industry to produce olodaterol for medical use.

Originator

Boehringer-Ingelheim (European Union)

Upstream product

• 869478-11-5 6-benzyloxy-8-((R)-2-chloro-1-hydroxyethyl)-4H-benzo[1,4]-oxazin-3-one 
• 869477-96-3 Olodaterol hydrochloride 
• 869478-13-7 6-benzyloxy-8-{(R)-1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylamino]ethyl}-4H-benzo[1,4]oxazin-3-one 

Downstream Products

• 869477-96-3 Olodaterol hydrochloride 

Relevant articles and documents

Olodaterol hydrochloride crystal form A and preparation method thereof

The invention relates to a long-acting beta 2 adrenergic agonist drug olodaterol hydrochloride crystal form A, a preparation method thereof and and a pharmaceutical composition containing the crystalform A. The crystal form is characterized by X-ray diffr

PROCESS FOR THE MANUFACTURING OF BETAMIMETICS

The present invention relates to a process for preparing betamimetics of formula 1, wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 denotes hydrogen, halogen, C1-4/su

NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG

The invention relates to enantiomerically pure compounds of formula (1), wherein the radicals R1, R2, R3, R4and X are defined as in claims and a description. A method for producing said compounds and the use thereof